|
|
Article: BTG Takes Exclusive License to New Class of Cancer Drug from Cancer Research Technology and The Institute of Cancer Research.
- Article from:
- Business Wire
- Article date:
- May 19, 2004
CopyrightCOPYRIGHT 2004 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors/Health/Medical Writers
WEST CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--May 19, 2004
BTG (LSE: BGC), the intellectual property and technology commercialization company, today announced that it has concluded a license and research collaboration agreement with Cancer Research Technology Limited (CRT), the technology transfer company of the charity Cancer Research UK, and The Institute of Cancer Research, for a new class of cancer drug.
Under the terms of this agreement (financial details were not disclosed), BTG has obtained exclusive worldwide rights to a series of novel quinazoline anti-tumor agents developed by Professor Ann Jackman ...